Biomaterial-Enabled Delivery Strategies to Overcome Treatment Resistance in Medulloblastoma
6 affiliations
- 1Department of Pediatric Neurosurgery, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China
- 2College of Life Science, Mudanjiang Medical University, Mudanjiang, Heilongjiang, People’s Republic of China
- 3Department of Neurosurgery, Huaihe Hospital of Henan University, Kaifeng, Henan, People’s Republic of China
- 4Changhai Clinical Research Unit, The First Affiliated Hospital of Naval Medical University, Shanghai, People’s Republic of China
- 5Shanghai Key Laboratory of Nautical Medicine and Translation of Drugs and Medical Devices, Shanghai Changhai Hospital, Shanghai, 200433, People’s Republic of China
- 6National Key Laboratory of Immunity and Inflammation, Naval Medical University, Shanghai, 200433, People’s Republic of China
Abstract
Multimodal therapy has improved survival in medulloblastoma (MB), yet recurrence, neuraxis dissemination, and treatment-related late effects remain major challenges. Treatment resistance reflects clonal evolution, drug efflux, altered DNA-damage and apoptotic responses, treatment-persistent cells, the tumor microenvironment, and inadequate active-drug exposure across the blood-brain barrier (BBB), postoperative residual compartments, and cerebrospinal fluid (CSF) spaces. Biomaterials can modify intracranial distribution, local retention, combination exposure, and intracellular cargo release. This review evaluates direct MB evidence for polymeric and lipid nanomedicines, biomimetic and virus-derived platforms, magnetic materials, extracellular vesicles, and hydrogels across intracranial solid lesions, postoperative residual disease, and neuraxis dissemination, while defining the limits of extrapolation from related tumors. Systemic nanomedicines currently provide the broadest evidence chain from formulation optimization to brain or tumor exposure, target modulation, and antitumor activity. Disease-matched studies also support active transendothelial transport and intrathecal nanoparticle therapy for metastatic MB. Most evidence remains preclinical; direct evidence of reversal of established treatment resistance is limited, and human studies largely assess route feasibility and safety. Progress will require quantitative active-cargo pharmacokinetics and pharmacodynamics, disease- and route-matched models, juvenile neurodevelopmental safety testing, and defined product quality attributes to determine whether these platforms can widen the therapeutic window or restore treatment sensitivity.
Related
- Biomaterial and bioorthogonal surface engineering of a modular dextran–lipid nanoplatform for tumorresponsive cytokine delivery
- DNA and mRNA Vaccines Against Hantaviruses: Antigen Design, Delivery Strategies and Translational Progress
- Nanoscale delivery systems for hepatocellular carcinoma: Functionalization, delivery strategies, and clinical challenges
- Self-Assembling Peptide Hydrogels for Mucosal Drug Delivery: Synthesis, Triggering Strategies, and Therapeutic Applications
- Hydrogel-based strategies for the controlled delivery of analgesic and anti-inflammatory drugs
BibTeX
@article{sheng2026biomaterialenabled,
title = {{Biomaterial-Enabled Delivery Strategies to Overcome Treatment Resistance in Medulloblastoma}},
author = {Zhiyuan Sheng and Yuxuan Dong and Jia Wei and Jinwei Li and Lingzhao Min and Yuanyuan Chen and Baocheng Wang and Yaxian Wen and Ying Xue Song and Jiajia Wang and Jie Gao and Xiaoqiang Wang},
journal = {International Journal of Nanomedicine},
year = {2026},
month = oct,
doi = {10.2147/ijn.s640704},
url = {https://doi.org/10.2147/ijn.s640704},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Biomaterial-Enabled Delivery Strategies to Overcome Treatment Resistance in Medulloblastoma
AU - Zhiyuan Sheng
AU - Yuxuan Dong
AU - Jia Wei
AU - Jinwei Li
AU - Lingzhao Min
AU - Yuanyuan Chen
AU - Baocheng Wang
AU - Yaxian Wen
AU - Ying Xue Song
AU - Jiajia Wang
AU - Jie Gao
AU - Xiaoqiang Wang
PY - 2026
DA - 2026/10/27
JO - International Journal of Nanomedicine
DO - 10.2147/ijn.s640704
UR - https://doi.org/10.2147/ijn.s640704
AB - Multimodal therapy has improved survival in medulloblastoma (MB), yet recurrence, neuraxis dissemination, and treatment-related late effects remain major challenges. Treatment resistance reflects clonal evolution, drug efflux, altered DNA-damage and apoptotic responses, treatment-persistent cells, the tumor microenvironment, and inadequate active-drug exposure across the blood-brain barrier (BBB), postoperative residual compartments, and cerebrospinal fluid (CSF) spaces. Biomaterials can modify intracranial distribution, local retention, combination exposure, and intracellular cargo release. This review evaluates direct MB evidence for polymeric and lipid nanomedicines, biomimetic and virus-derived platforms, magnetic materials, extracellular vesicles, and hydrogels across intracranial solid lesions, postoperative residual disease, and neuraxis dissemination, while defining the limits of extrapolation from related tumors. Systemic nanomedicines currently provide the broadest evidence chain from formulation optimization to brain or tumor exposure, target modulation, and antitumor activity. Disease-matched studies also support active transendothelial transport and intrathecal nanoparticle therapy for metastatic MB. Most evidence remains preclinical; direct evidence of reversal of established treatment resistance is limited, and human studies largely assess route feasibility and safety. Progress will require quantitative active-cargo pharmacokinetics and pharmacodynamics, disease- and route-matched models, juvenile neurodevelopmental safety testing, and defined product quality attributes to determine whether these platforms can widen the therapeutic window or restore treatment sensitivity.
SN - 1176-9114
SN - 1178-2013
ER -